{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:05:52Z","timestamp":1779267952094,"version":"3.51.4"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) and IgA nephropathy (IgAN) are immune-mediated renal disorders characterized by aberrant B-cell activation. While SLE shows a striking female predominance, IgAN is more prevalent in males; nonetheless, both conditions typically peak the during reproductive years. Their pathogenesis involves distinct molecular drivers: SLE is mediated by specific autoantibodies, whereas IgAN is initiated by galactose-deficient IgA1 (Gd-IgA1) acting as a primary antigen that elicits immune complex deposition. Conventional immunosuppressive therapies are effective but limited by non-selective toxicity, particularly in women of reproductive age. Telitacicept, a first-in-class recombinant transmembrane activator and CAML interactor (TACI)\u2013fragment crystallizable (Fc) fusion protein, simultaneously neutralizes B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), offering a targeted pharmacological strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review synthesizes evidence from randomized controlled trials, real-world studies, and mechanistic investigations to evaluate the pharmacological rationale, clinical efficacy, and safety profile of telitacicept in SLE and IgAN, with particular attention to its steroid-sparing effects and endocrine safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dual inhibition of BAFF and APRIL by telitacicept suppresses pathological B-cell maturation and plasma cell survival, leading to marked reductions in antigen Gd-IgA1 and associated immune complexes, proteinuria, and disease activity, alongside stabilization of renal function. Clinical trials and real-world data demonstrate robust efficacy in both refractory IgAN and active SLE\/lupus nephritis, with sustained complement recovery and favorable tolerability. Importantly, available clinical data indicate no direct gonadotoxic effects, with preserved ovarian reserve markers and hypothalamic\u2013pituitary\u2013gonadal axis function, distinguishing telitacicept from cytotoxic immunosuppressants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept represents a pharmacologically rational, targeted immunomodulator that combines effective disease control with a favorable safety profile. Its dual BAFF\/APRIL inhibition and steroid-sparing properties support its potential role as a long-term therapeutic option for patients with SLE and IgAN, particularly women requiring sustained disease control who seek to minimize systemic toxicity and safeguard ovarian reserve.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1794203","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:11:00Z","timestamp":1779264660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual BAFF\/APRIL inhibition with telitacicept in systemic lupus erythematosus and IgA nephropathy: pharmacological rationale, clinical efficacy, and safety on female fertility preservation"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongzhu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"L\u00fc","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyue","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jilin City People\u2019s Hospital","place":["Jilin City, Jilin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.18295\/squmj.2021.21.02.013","article-title":"Pregnancy outcomes in systemic lupus erythematosus women","volume":"21","author":"Al-Riyami","year":"2021","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/bcp.70103","article-title":"Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: analysis of exposure and disease activity","volume":"91","author":"Bouazza","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1177\/09612033211050340","article-title":"Systemic lupus erythematosus and pregnancy: a retrospective single-center study of 215 pregnancies from Portugal","volume":"30","author":"Braga","year":"2021","journal-title":"Lupus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1169084","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s41927-023-00358-3","article-title":"Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE)","volume":"7","author":"Chan","year":"2023","journal-title":"BMC Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/0961203319839482","article-title":"Successful conception in a 34-year-old lupus patient following spontaneous pregnancy after autotransplantation of cryopreserved ovarian tissue","volume":"28","author":"Chehab","year":"2019","journal-title":"Lupus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00296-017-3733-2","article-title":"Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses","volume":"37","author":"Chen","year":"2017","journal-title":"Rheumatol. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13075-025-03584-x","article-title":"Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus","volume":"27","author":"Chen","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2449580","DOI":"10.1080\/0886022X.2025.2449580","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a real-world study","volume":"47","author":"Dong","year":"2025","journal-title":"Ren. Fail."},{"key":"B11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12884-024-06632-7","article-title":"Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report","volume":"24","author":"Du","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today"},{"key":"B13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12884-023-05941-7","article-title":"Clinical features and prognosis of pregnancy-related renal damage and pregnancy after chronic kidney disease","volume":"23","author":"Fang","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1472292","DOI":"10.3389\/fimmu.2024.1472292","article-title":"Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis","volume":"15","author":"Gao","year":"2025","journal-title":"Front. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1390783","DOI":"10.3389\/fneph.2024.1390783","article-title":"Lupus nephritis: management challenges during pregnancy","volume":"4","author":"Gholizadeh Ghozloujeh","year":"2024","journal-title":"Front. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/1756-185X.14613","article-title":"Safety, efficacy and pharmacokinetics of low\u2010dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus","volume":"26","author":"Guan","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/09612033241311330","article-title":"The effectiveness of telitacicept in patients with systemic lupus erythematosus: a retrospective, real-world study","volume":"34","author":"Hu","year":"2025","journal-title":"Lupus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1177\/0961203318770536","article-title":"The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus","volume":"27","author":"Ichinose","year":"2018","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40620-021-00979-2","article-title":"Pregnancy outcomes in women with immunoglobulin a nephropathy: a nationwide population-based cohort study","volume":"34","author":"Jarrick","year":"2021","journal-title":"J. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1232244","DOI":"10.3389\/fimmu.2023.1232244","article-title":"Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Jiang","year":"2023","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/ndt\/gfaf049","article-title":"Real world data on dual BLyS\/APRIL inhibition with telitacicept for lupus nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Nephrol. Dial. Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.beem.2019.101369","article-title":"Infertility in women with systemic autoimmune diseases","volume":"33","author":"Khizroeva","year":"2019","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s10067-025-07377-0","article-title":"A nomogram for predicting the adverse pregnancy outcomes of systemic lupus erythematosus: a single-center study","volume":"44","author":"Kong","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0159364","DOI":"10.1371\/journal.pone.0159364","article-title":"Pregnancy outcomes in Chinese patients with systemic lupus erythematosus (SLE): a retrospective study of 109 pregnancies","volume":"11","author":"Ku","year":"2016","journal-title":"PLOS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaut.2016.06.016","article-title":"A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus","volume":"74","author":"Lazzaroni","year":"2016","journal-title":"J. Autoimmun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105713","DOI":"10.1016\/j.jbspin.2024.105713","article-title":"Issues with pregnancy in systemic lupus","volume":"91","author":"Le Guern","year":"2024","journal-title":"Jt. Bone Spine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2486620","DOI":"10.1080\/0886022X.2025.2486620","article-title":"Causal associations between environmental factors and risk of IgA nephropathy and membranous nephropathy: a bidirectional mendelian randomization and mediation analysis","volume":"47","author":"Li","year":"","journal-title":"Ren. Fail."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1564242","DOI":"10.3389\/fimmu.2025.1564242","article-title":"Efficacy of telitacicept in treating IgA vasculitis nephritis: a two-case report","volume":"16","author":"Li","year":"","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12882-021-02633-2","article-title":"Fetal and maternal outcome in patients with active lupus nephritis: comparison between new-onset and pre-existing lupus nephritis","volume":"22","author":"Lian","year":"2021","journal-title":"Bmc Nephrol."},{"key":"B31","volume-title":"Efficacy and Safety of Telitacicept in Patients with Iga Nephropathy","author":"Liang","year":"2026"},{"key":"B32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1053\/j.ajkd.2014.06.021","article-title":"Risk factors for pregnancy outcomes in patients with IgA nephropathy: a matched cohort study","volume":"64","author":"Liu","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.12669\/pjms.39.4.7542","article-title":"A new promising biological agent for refractory lupus nephritis: telitacicept","volume":"39","author":"Liu","year":"2023","journal-title":"Pak. J. Med. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540326","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study","volume":"149","author":"Liu","year":"","journal-title":"Nephron"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1111\/ijd.17321","article-title":"Response to telitacicept in systemic lupus erythematosus patients: a real-world, single-center observational study in China","volume":"63","author":"Liu","year":"","journal-title":"Int. J. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1613790","DOI":"10.3389\/fphar.2025.1613790","article-title":"Efficacy and safety of telitacicept in systemic lupus erythematosus with lupus nephritis and nephrotic syndrome: a 12-month retrospective cohort study","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12884-024-06701-x","article-title":"Pregnancy outcomes and risk factors analysis in patients with systemic lupus erythematous","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol. Dial. Transpl."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.010","article-title":"Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study","volume":"74","author":"Moroni","year":"2016","journal-title":"J. Autoimmun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-023-03256-8","article-title":"A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers","volume":"26","author":"Nakai","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials","volume":"70","author":"Palmer","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/1744666X.2015.1033404","article-title":"Immunosuppression in pregnant women with systemic lupus erythematosus","volume":"11","author":"Ponticelli","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.12998\/wjcc.v13.i19.101196","article-title":"Treatment of immunoglobulin a nephropathy: current perspective and future prospects","volume":"13","author":"\u015eener","year":"2025","journal-title":"World J. Clin. Cases"},{"key":"B46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13075-020-02292-y","article-title":"Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study","volume":"22","author":"Sharma","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"sfaf251","DOI":"10.1093\/ckj\/sfaf251","article-title":"Novel therapies improve prognosis of IgAN and limit the applicability of the international IgA nephropathy prediction tool","volume":"18","author":"Shen","year":"2025","journal-title":"Clin. Kidney J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.2169\/internalmedicine.54.5071","article-title":"Effect of pregnancy and delivery on the renal function and the prognosis of patients with chronic kidney disease stage 3 caused by immunoglobulin a nephropathy","volume":"54","author":"Shimizu","year":"2015","journal-title":"Intern. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.ajkd.2017.01.043","article-title":"Pregnancy and kidney outcomes in patients with IgA nephropathy: a cohort study","volume":"70","author":"Su","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00404-025-08106-3","article-title":"Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review","volume":"312","author":"Sun","year":"2025","journal-title":"Arch. Gynecol. Obstet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000496410","article-title":"Renal outcomes of pregnant patients with immunoglobulin a nephropathy: a systematic review and meta-analysis","volume":"49","author":"Wang","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"sfaf154","DOI":"10.1093\/ckj\/sfaf154","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes","volume":"18","author":"Weng","year":"2025","journal-title":"Clin. Kidney J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2665-9913(24)00160-7","article-title":"Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"6","author":"Wind","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s40001-023-01320-2","article-title":"Role of telitacicept in the treatment of IgA nephropathy","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/nep.14340","article-title":"Current understanding and new insights in the treatment of IgA nephropathy","volume":"29","author":"Zhang","year":"2024","journal-title":"Nephrology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e21121","DOI":"10.1097\/MD.0000000000021121","article-title":"Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: a PRISMA-Compliant meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Med. Baltim."},{"key":"B59","doi-asserted-by":"publisher","first-page":"20251158","DOI":"10.1515\/biol-2025-1158","article-title":"A case of IgA nephropathy treated with a combination of telitacicept and half-dose glucocorticoids","volume":"20","author":"Zhang","year":"","journal-title":"Open Life Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1610136","DOI":"10.3389\/fimmu.2025.1610136","article-title":"Impact of telitacicept on gonadal function in adult female patients with systemic lupus erythematosus: a prospective cohort study","volume":"16","author":"Zhang","year":"","journal-title":"Front. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3892\/etm.2024.12660","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis","volume":"28","author":"Zhu","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cdt3.104","article-title":"Advances in the treatment of IgA nephropathy with biological agents","volume":"10","author":"Zhuang","year":"2024","journal-title":"Chronic Dis. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:11:02Z","timestamp":1779264662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1794203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":62,"alternative-id":["10.3389\/fphar.2026.1794203"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1794203","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1794203"}}